1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: other
Brother Enterprises Holding Co., Ltd. Class A

Brother Enterprises Holding Co., Ltd. Class A

SSZSE:002562
4.46
CNY
+0.05
(+1.13%)
0.12EPS
36.11P/E
4.97BMarket Cap
Oct 28Next Earn
Brother Enterprises Holding Co., Ltd. Class A
SZSE:002562
(Shenzhen Stock Exchange)

Recent

price

4.46

P/E

ratio

36.11

div

yld

3.17%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
1.16
1.02
1.15
1.2
1.19
1.31
1.27
1.82
1.95
1.43
2.05
2.89
3.24
2.73
3.37
3.42
3.42
Revenue per Share
0.1
0.08
-0.08
0.03
0.06
0.12
0.2
0.47
0.03
0.05
0.03
0.03
0.29
-0.17
0.04
0.09
0.12
Basic EPS, GAAP
0.03
-0.24
0.1
0.01
- -
0.01
-0.21
-0.23
-0.3
-0.74
-0.36
-0.19
-0.01
-0.35
-0.1
-0.06
- -
Free Cash Flow per Basic Share
0.03
0.01
0.05
0.02
0.01
0.04
- -
0.06
0.15
0.11
0.04
0.03
0.04
0.18
0.05
0.05
0.14
Dividend per Share
0.51
1.22
1.12
1.15
1.21
1.93
2.04
2.64
2.57
2.57
3.19
2.82
3.17
2.87
2.91
3.23
3.19
Book Value per Share
0.45
1.18
1.08
1.11
1.16
1.83
1.94
2.5
2.44
2.44
3.01
2.65
3.01
2.72
2.77
3.1
3.07
Tangible Book Value per Share
513
606
672
655
674
693
838
858
727
877
934
944
1,054
1,032
1,020
1,057
1,123
Basic Weighted Avg Shares
597
621
775
784
801
905
1,063
1,565
1,415
1,258
1,919
2,733
3,411
2,821
3,441
3,612
3,840
Sales/Revenue/Turnover
12.63
12.22
2.98
4.48
6.55
12.81
19.46
31.67
4.68
4.75
8.18
1.82
13.84
-1.76
4.11
6.47
7.57
Operating Margin (%)
25
30
33
38
54
59
60
113
146
164
248
291
312
325
353
380
- -
Depreciation Expense
50
51
-57
18
40
82
168
403
22
44
28
28
306
-175
41
95
135
Net Income, GAAP
15.33
10.3
- -
14.74
15.47
10.03
16.78
14.69
66.47
7.62
31.96
- -
18.73
- -
20.49
15.8
12.56
Effective Tax Rate (%)
8.45
8.23
-7.32
2.35
5
9.08
15.77
25.76
1.54
3.48
1.46
1.04
8.96
-6.22
1.19
2.63
3.52
Profit Margin (%)
-30
510
639
296
312
1,051
558
1,319
667
440
556
470
376
-886
-652
334
391
Working Capital
19
- -
250
- -
- -
- -
1
528
505
763
841
883
528
144
317
629
681
LT Debt
282
860
791
800
839
1,705
1,764
2,286
2,259
2,317
3,027
2,995
3,373
3,054
3,100
3,688
3,647
Total Equity
10.17
7.77
- -
0.73
3.71
7.13
11.24
17.39
0.83
1.47
0.82
- -
6.89
- -
0.89
2
2.73
Return on Invested Capital (%)
12.95
7.04
- -
4.36
4.82
4.78
8.25
17.49
1.14
2.35
1.56
- -
7.58
- -
1.81
2.79
3.42
Return on Capital (%)
21.34
9.32
-7.08
2.37
4.97
6.59
9.76
19.91
0.96
1.92
1.05
0.94
9.6
-5.46
1.33
2.8
4
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
964
913
890
LT Borrowings
620
680
673
LT Finance Leases
8
8
9
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,143
1,143
1,143
Market Capitalization
7,383
6,960
4,971

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
2,123
2,148
2,133
Cash, Cash Equivalents & STI
522
522
550
Accounts Receivable, Net
467
567
528
Inventories
987
910
937
Total Current Liabilities
1,789
1,718
1,742
Payables & Accruals
- -
- -
- -
ST Debt
964
913
890
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
8.76%
4.52%
18.98%
Free Cash Flow
-231.53%
414.25%
-34.49%
Net Income, GAAP
104.64%
166.37%
133.02%
Sales/Revenue/Turnover
17.34%
15.38%
4.95%
Total Cash Common Dividend
2,948.31%
59.9%
-7.43%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
820
931
849
842
3,441
2025
919
892
- -
886
3,612
2026
987
1,074
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.02
0.04
0.02
0.01
0.04
2025
0.02
0.04
- -
-0.01
0.09
2026
0.03
0.05
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.01
0.01
0.01
0.05
2025
0.01
0.01
- -
0.01
0.05
2026
0.01
0.11
- -
- -
- -
Similar Companies
Cipla Ltd (NSE:CIPLA)
Aurobindo Pharma Ltd (NSE:AUROPHARMA)
Lupin Limited (NSE:LUPIN)
Granules India Limited (NSE:GRANULES)
Revolution Medicines, Inc. (NASDAQ:RVMD)
Egyptian International Pharmaceutical Industries Co. (EGX:PHAR)
Business
Brother Enterprises Holding Co., Ltd. (002562.SZ) engages primarily in the research, development, manufacture, and sale of nutritional feed additives and premixes for the animal nutrition industry. The company offers a comprehensive portfolio of products including vitamins such as vitamin A, vitamin D3, vitamin E, vitamin C, and biotin; carotenoids like beta-carotene and canthaxanthin; and premixes tailored for livestock, poultry, aquatic animals, and pets; as well as services in customized formulation and technical support for feed production. It operates through segments encompassing vitamin production, premix blending, and chemical synthesis, serving major customers in animal husbandry, aquaculture, and pet food sectors across China and select international markets including Southeast Asia and Europe. Founded in 1998 and headquartered in Ningbo, Zhejiang Province, China, the company maintains production facilities in multiple provinces and subsidiaries focused on R&D and global distribution. In recent developments, Brother Enterprises has expanded its production capacity through strategic investments in new vitamin synthesis lines and formed alliances with international partners for sustainable sourcing of raw materials; additionally, it launched enhanced premix solutions for antibiotic-free animal feed in 2024 amid China's regulatory shifts toward greener agriculture, while pursuing acquisitions in the functional feed additives space to bolster its market position.